Home β€Ί Stock analysis β€Ί XRTX

XORTX Therapeutics (XRTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

XRTX slides 12.7% to $1.24, a 52-week low, 4 down days in a row. Closed at $1.24, -12.68% vs the prior close of $1.42. Day range $1.21–$1.42, opened at $1.39.

Last close$1.24-12.68%
Day range1.21–1.42
Open1.39
Volume91.93K
52-week range1.21–7.05
Avg volume (20d)1.61M

XRTX daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” XRTX slides 12.7% to $1.24, a 52-week low, 4 down days in a row
Oct 15, 2026 β€” XRTX slides 9.0% to $1.42, 3 down days in a row
Oct 14, 2026 β€” XRTX slides 7.1% to $1.56
Oct 13, 2026 β€” XRTX dips 2.3% to $1.68
Oct 12, 2026 β€” XRTX jumps 22.0% to $1.72 on 2.0x normal volume
Oct 9, 2026 β€” XRTX slides 23.8% to $1.41, a 52-week low on 37.5x normal volume
Oct 8, 2026 β€” XRTX jumps 6.0% to $1.85 on 37.5x normal volume
Oct 7, 2026 β€” XRTX rises 0.9% to $1.75
Oct 6, 2026 β€” XRTX rises 1.8% to $1.73
Oct 5, 2026 β€” XRTX dips 0.8% to $1.70
Oct 2, 2026 β€” XRTX dips 0.9% to $1.71

XRTX latest news & SEC filings

Every SEC filing by or about XRTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 8, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-006540

Sep 18, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-006109

Sep 10, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-005981

Sep 9, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001185185-26-003895

Sep 4, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001185185-26-003845

Aug 28, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-005782

Aug 17, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-005562

Aug 4, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-005158

Jul 29, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001171843-26-004972

Things to know before you trade XRTX

XRTX market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 20261.391.421.211.2491.93K
Oct 15, 20261.531.541.411.42125.40K
Oct 14, 20261.601.711.561.5677.10K
Oct 13, 20261.621.731.511.68177.20K
Oct 12, 20261.401.901.391.721.76M
Oct 9, 20262.052.081.361.4118.65M
Oct 8, 20261.751.901.721.8510.68M
Oct 7, 20261.731.751.691.7521.70K
Oct 6, 20261.751.791.711.7340.70K
Oct 5, 20261.731.731.691.708.90K
Oct 2, 20261.721.791.701.714.40K
Oct 1, 20261.691.751.691.7322.10K
Sep 30, 20261.701.721.691.6925.90K
Sep 29, 20261.701.741.691.7071.40K
Sep 28, 20261.691.741.691.7129.80K
Sep 25, 20261.741.821.691.6946.70K
Sep 24, 20261.691.781.691.7251.30K
Sep 23, 20261.801.831.691.7058.80K
Sep 22, 20261.911.931.781.8677.20K
Sep 21, 20261.992.091.851.95224.70K

About XORTX Therapeutics

XORTX Therapeutics (XRTX) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in VANCOUVER, British Columbia, Canada. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1729214.

XRTX board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
No Form 3/4/5 filings by this group in the last 12 months.

Executive officers

NameTitleLatest filing
No Form 3/4/5 filings by this group in the last 12 months.

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

XRTX financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

XRTX earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on XRTX

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.